Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation

Leukemia

Volumn 19, Issue 5, 2005, Pages 814-821

  Zeiser, R ^a,c   Spyridonidis, A ^a   Wasch R ^a   Ihorst, G ^b   Grullich C ^a   Bertz, H ^a   Finke, J ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute myeloid leukemia; Allogeneic hematopoietic cell transplantation; Chimerism analysis; Immunotherapy; Myelodysplastic syndrome

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ARTICLE; CANCER REGRESSION; CANCER RISK; CELL LINEAGE; CELL SEPARATION; CHIMERA; CONTROLLED STUDY; DONOR; FOLLOW UP; GRAFT REJECTION; HUMAN; IMMUNOMODULATION; LEUKEMIA RELAPSE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MICROSATELLITE MARKER; MYELODYSPLASTIC SYNDROME; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PATIENT MONITORING; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY;

EID: 18644365146     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403719     Document Type: Article

References (40)

1. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73: 1720-1728.
2. van Rhee F, Lin F, Cullis JO, Spencer A, Cross NC, Chase A et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994; 83: 3377-3383.
3. Dazzi F, Szydlo RM, Goldman JM. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand. Exp Hematol 1999; 27: 1477-1486.
4. Bader P, Klingebiel T, Schaudt A, Theurer-Mainka U, Handgretinger R, Lang P et al. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children. Leukemia 1999; 13: 2079-2086.
5. Salama M, Nevill T, Marcellus D, Parker P, Johnson M, Kirk A et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000; 26: 1179-1184.
6. Lokhorst HM, Schattenberg A, Cornelissen JJ, van Oers MH, Fibbe W, Russell I et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000; 18: 3031-3037.
7. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia (see comments). Blood 1995; 86: 2041-2050.
8. van Besien KW, Lima M, Giralt SA, Moore Jr DF, Khouri IF, Rondon G et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplantation 1997; 19: 977-982.
9. Mackinnon S, Barnett L, Bourhis JH, Black P, Heller G, O'Reilley RJ. Myeloid and lymphoid chimaerism after T-cell depleted bone marrow transplantation: evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatellite regions of genomic DNA. Blood 1992; 80: 3235-3241.
10. van Leeuwen JEM, van Tol MJD, Joosten AM, Wijnen JT, Verweij PJ, Khan PM et al. Persistence of host-type hematopoiesis after allogeneic bone marrow transplantation for leukemia is significantly related to the recipient's age and/or the conditioning regimen, but is not associated with an increased risk of relapse. Blood 1994; 83: 3059-3067.
11. Mattsson J, Uzunel M, Tammik L, Aschan J, Ringdén O. Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation. Leukemia 2001; 15: 1976-1985.
12. Lion T, Daxberger H, Dubovsky J, Filipcik P, Fritsch G, Printz D et al. Analysis of chimersim within specific leukocyte subsets for detection of residual or recurrent leukemia in pediatric patients after allogeneic stem cell transplantation. Leukemia 2001; 15: 307-310.
13. Thiede CH, Lutterbeck K, Oelschlagel U, Kiehl M, Steudel CH, Platzbecker U et al. Detection of relapse by sequential monitoring of chimerism circulating CD34+ cells. Ann Hematol 2002; 81 (Suppl 2): 27-28.
14. Finke J, Bertz H, Schmoor C, Veelken H, Behringer D, Wäsch R et al. Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T-cell globulin. Br J Haematol 2000; 111: 303-313.
15. Wäsch R, Reisser S, Hahn J, Bertz H, Engelhardt M, Kunzmann R et al. Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation. Bone Marrow Transplant 2000; 26: 243-250.
16. Greenberg P, Anderson J, de Witte T, Estey E, Fenaux P, Gupta P et al. Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group. J Clin Oncol 2000; 18: 3447-3452.
17. Polymeropoulos MH, Rath DS, Xiao H, Merril CR. Tetranucleotide repeat polymorphism at the human beta-actin related pseudogene H-beta-Ac-psi-2 (ACTBP2). Nucleic Acids Res 1992; 20: 1432.
18. Edwards A, Hammond HA, Jin L, Caskey CT, Chakraborty R. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics 1992; 12: 241-253.
19. Budowle B, Chakraborty R, Giusti AM, Eisenberg AJ, Allen RC. Analysis of the VNTR locus D1S80 by the PCR followed by high-resolution PAGE. Am J Hum Genet 1991; 48: 137-144.
20. Gerken SC, Matsumani N, Lawrence E, Moore M, Ballard L, Melis R et al. Genetic and physical mapping of a simple repeat containing sequence tagged sites from the human genome. Genome Data Base Accession ID: GDB 198597, 1993.
21. Mastana S, Lee D, Singh PP, Singh M. Molecular genetic variation in the East Midlands, England: analysis of VNTR, STR and Alu insertion/deletion polymorphisms. Ann Hum Biol 2003; 30: 538-550.
22. Marubini E, Valsecchi MG. Analysing Survival Data from Clinical Trials and Observational Studies. John Wiley Press: New York, 1995.
23. Pepe MS. The Statistical Evaluation of Medical Tests for Classification and Prediction. Oxford University Press: New York, NY, 2003.
24. Kolb HJ. Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties. Vox Sang 1998; 74: 321-329.
25. Pratt W, Ruddon R, Ensminger W, Maybaum J. Determinants of Drug Responsiveness. Oxford University Press: New York, NY, 1994.
26. Elmaagacli AH, Beelen DW, Kroll M, Trzensky S, Stein C, Schaefer UW. Detection of CBFbeta/MYH11 fusion transcripts in patients with inv (16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation. Bone Marrow Transplant 1998; 21: 159-166.
27. Krauter J, Gorlich K, Ottmann O, Lubbert M, Dohner H, Heit W et al. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias. J Clin Oncol 2003; 21: 4413-4422.
28. Campana D, Pui CH. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 1995; 85: 1416-1434.
29. Schattenberg A, De Witte T, Salden M, Vet J, Van Dijk B, Smeets D et al. Mixed hematopoietic chimerism after allogeneic transplantation with lymphocyte-depleted bone marrow is not associated with a higher incidence of relapse. Blood 1989; 73: 1367-1372.
30. van Leeuwen JE, van Tol MJ, Joosten AM, Wijnen JT, Khan PM, Vossen JM. Mixed T-lymphoid chimerism after allogeneic bone marrow transplantation for hematologic malignancies of children is not correlated with relapse. Blood 1993; 82: 1921-1928.
31. Bader P, Beck J, Frey A, Schlegel PG, Hebarth H, Handgretinger R et al. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT. Bone Marrow Transplant 1998; 21: 487-495.
32. Bader P, Kreyenberg H, Hoelle W, Dueckers G, Handgretinger R, Lang P et al. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy. J Clin Oncol 2004; 22: 1696-1706.
33. Zetterquist H, Mattsson J, Uzunel M, Näsman-Björk I, Svenberg P, Tammik L et al. Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B-cell acute lymphoblastic leukemia. Bone Marrow Transplant 2000; 25: 843-851.
34. Dubovsky J, Daxberger H, Fritsch G, Printz D, Peters C, Matthes S et al. Kinetics of chimerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders: implications for timely detection of engraftment, graft failure and rejection. Leukemia 1999; 13: 2059-2060.
35. Lamb Jr LS, Robbins NF, Abhyankar S, Joyce M, Stetler-Stevenson M, Henslee-Downey PJ et al. Flow cytometric cell sorting combined with molecular chimerism analysis to detect minimal recurrent leukemia: good news and bad news. Bone Marrow Transplant 1997; 19: 1157-1161.
36. Estrov Z, Ouspenskaia MV, Felix EA, McClain KL, Lee MS, Harris D et al. Persistence of self-renewing leukemia cell progenitors during remission in children with B-precursor acute lymphoblastic leukemia. Leukemia 1994; 8: 46-52.
37. Lauria F, Raspadori D, Ventura MA, Rondelli D, Testoni N, Tosi P et al. The presence of lymphoid-associated antigens in adult acute myeloid leukemia is devoid of prognostic relevance. Stem Cells 1995; 13: 428-434.
38. Goulden NJ, Knechtli CJ, Garland RJ, Langlands K, Hancock JP, Potter MN et al. Minimal residual disease analysis for the prediction of relapse in children with standard-risk acute lymphoblastic leukaemia. Br J Haematol 1998; 100: 235-244.
39. Simmons PJ, Przepiorka D, Thomas ED, Torok-Storb B. Host origin of marrow stromal cells following allogeneic bone marrow transplantation. Nature 1987; 328: 429-432.
40. Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LL, Verdonck LF. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997; 90: 4206-4211.